IN BRIEF: MaxCyte to consolidate two lines of common stock into one

Thu, 13th May 2021 19:16

MaxCyte Inc - Maryland-based cell and gene therapies firm - Announces the consolidation of two of its lines of common stock into a single unrestricted line.

The consolidation will be effected by the transfer of all stock comprising the Regulation S restricted trading line, or MXCL to the unrestricted common stock trading line, also known as MXCT.

Following the consolidation, MaxCyte will have 84.4 million shares under the MXCT trading line issued overall.

Current stock price: 883.00 pence

Year-to-date change: up 67%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Related Shares

More News

3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

30 Apr 2024 14:38

UK earnings, trading statements calendar - next 7 days

2 Apr 2024 15:19

TRADING UPDATES: MaxCyte inks deal with Be Bio; Orcadian firms farmout

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

13 Mar 2024 12:04

MaxCyte reports strong fourth quarter as full-year revenues fall

(Sharecast News) - Cell engineering technology specialist MaxCyte reported total fourth quarter revenue of $15.7m on Wednesday, up 26% on the same per...

13 Mar 2024 11:54

IN BRIEF: MaxCyte loss widens in 2023 as core revenue declines 25%

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Net loss w...